Evidence map›Paper›PMID 27434221›Full record

Trial reportInternational journal of obesity (2005)2016

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.

M S Svane, N B Jørgensen, K N Bojsen-Møller, C Dirksen, S Nielsen, V B Kristiansen, S Toräng, N J Wewer Albrechtsen, J F Rehfeld, B Hartmann and 2 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of obesity (2005), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Methodological issues in assessing change in dietary intake and appetite following gastric bypass surgery: A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. GIP(3-30)NHDiabetologia · 2018
    Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Review
  15. Cholecystokinin: Clinical aspects of the new biology.Journal of internal medicine · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Triple Agonism Based Therapies for Obesity.Current cardiovascular risk reports · 2025
    Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

M S SvaneDepartment of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
N B JørgensenDepartment of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
K N Bojsen-MøllerDepartment of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
C DirksenDepartment of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
S NielsenDepartment of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
V B KristiansenDepartment of Surgical Gastroenterology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
S TorängNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
N J Wewer AlbrechtsenNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
J F RehfeldDepartment of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
B HartmannNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
S MadsbadDepartment of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
J J HolstNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Copenhagen University Hospital · DKNovo Nordisk Foundation · DKHvidovre Hospital · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesExaggerated postprandial secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) may explain appetite reduction and weight loss after Roux-en-Y gastric bypass (RYGB), but causality has not been established. We hypothesized that food intake decreases after surgery through combined actions from GLP-1 and PYY. GLP-1 actions can be blocked using the GLP-1 receptor antagonist Exendin 9-39 (Ex-9), whereas PYY actions can be inhibited by the administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor preventing the formation of PYY SUBJECTS/

methodsAppetite-regulating gut hormones and appetite ratings during a standard mixed-meal test and effects on subsequent ad libitum food intake were evaluated in two studies: in study 1, nine patients with type 2 diabetes were examined prospectively before and 3 months after RYGB with and without Ex-9. In study 2, 12 RYGB-operated patients were examined in a randomized, placebo-controlled, crossover design on four experimental days with: (1) placebo, (2) Ex-9, (3) the DPP-4 inhibitor, sitagliptin, to reduce formation of PYY

resultsIn study 1, food intake decreased by 35% following RYGB compared with before surgery. Before surgery, GLP-1 receptor blockage increased food intake but no effect was seen postoperatively, whereas PYY secretion was markedly increased. In study 2, combined GLP-1 receptor blockage and DPP-4 inhibitor mediated lowering of PYY

conclusionsBlockade of actions from only one of the two L-cell hormones, GLP-1 and PYY

Indexed as

Gastric BypassAppetiteAppetite RegulationCross-Over StudiesDenmarkDiabetes Mellitus, Type 2EatingFemaleGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansMaleObesity, MorbidPeptide FragmentsPeptide YYTreatment Outcomeexendin (9-39)Glucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorPeptide FragmentsPeptide YY

Identifiers

PMID27434221
OpenAlexW2484284074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.